Food safety and GM crops implications for developing-country research

"In the developing world the approval and cultivation of genetically modified (GM) crops is largely limited to the commercial production of insect-resistant cotton in Argentina, China, India, Mexico, and South Africa.... Approvals of GM crops used for food or feed lag far behind cotton... This gap in approvals is unfortunate, because crop biotechnology, appropriately applied, has the potential to address key production constraints affecting resource-poor farmers. Currently, important public- and private-sector research is underway to help meet the productivity needs of these farmers." from TextFood safety ,food security ,Public health ,

Direct Measurement of Kirkwood-Rihaczek distribution for spatial properties of coherent light beam

We present direct measurement of Kirkwood-Rihaczek (KR) distribution for spatial properties of coherent light beam in terms of position and momentum (angle) coordinates. We employ a two-local oscillator (LO) balanced heterodyne detection (BHD) to simultaneously extract distribution of transverse position and momentum of a light beam. The two-LO BHD could measure KR distribution for any complex wave field (including quantum mechanical wave function) without applying tomography methods (inverse Radon transformation). Transformation of KR distribution to Wigner, Glauber Sudarshan P- and Husimi or Q- distributions in spatial coordinates are illustrated through experimental data. The direct measurement of KR distribution could provide local information of wave field, which is suitable for studying particle properties of a quantum system. While Wigner function is suitable for studying wave properties such as interference, and hence provides nonlocal information of the wave field. The method developed here can be used for exploring spatial quantum state for quantum mapping and computing, optical phase space imaging for biomedical applications.Comment: 27 pages, 14 figure

Giant Helium Dimers Produced by Photoassociation of Ultracold Metastable Atoms

We produce giant helium dimers by photoassociation of metastable helium atoms in a magnetically trapped, ultracold cloud. The photoassociation laser is detuned red of the atomic $2^3S_1 - 2^3P_0$ line and produces strong heating of the sample when resonant with molecular bound states. The temperature of the cloud serves as an indicator of the molecular spectrum. We report good agreement between our spectroscopic measurements and our calculations of the five bound states belonging to a $0_u^+$ purely long-range potential well. These previously unobserved states have classical inner turning points of about 150 $a_0$ and outer turning points as large as 1150 $a_0$.Comment: 4 pages, 4 figure

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Background: Patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) receiving platinum-based chemotherapy as their first-line treatment have a dismal prognosis, with a median overall survival (OS) of ~7 months. Methotrexate is sometimes used following platinum failure or in patients not fit enough for platinum therapy, but this agent has not demonstrated any OS improvement. Targeted therapies are a novel approach, with the EGFR-targeting monoclonal antibody cetuximab (plus platinum-based chemotherapy) approved in the US and Europe in the first-line R/M setting, and as monotherapy following platinum failure in the US. However, there is still a high unmet medical need for new treatments that improve outcomes in the second-line R/M setting following failure on first-line platinum-containing regimens. Afatinib, an irreversible ErbB family blocker, was recently approved for the first-line treatment of EGFR mutation-positive metastatic non-small cell lung cancer. Afatinib has also shown clinical activity similar to cetuximab in a Phase II proof-of-concept HNSCC trial. Based on these observations, the Phase III, LUX-Head & Neck 1 study is evaluating afatinib versus methotrexate in R/M HNSCC patients following progression on platinum-based chemotherapy in the R/M setting. Methods/Design Patients with progressive disease after one first-line platinum-based chemotherapy are randomised 2:1 to oral afatinib (starting dose 40 mg once daily) or IV methotrexate (starting dose 40 mg/m2 once weekly) administered as monotherapy with best supportive care until progression or intolerable adverse events. Efficacy of afatinib versus methotrexate will be assessed in terms of progression-free survival (primary endpoint). Disease progression will be evaluated according to RECIST v1.1 by investigator and independent central review. Secondary endpoints include OS, tumour response and safety. Health-related quality of life and biomarker assessments will also be performed. Discussion If the LUX-Head & Neck 1 trial meets its primary endpoint, it will demonstrate the ability of afatinib to elicit an improved treatment benefit versus a commonly used chemotherapy agent in the second-line treatment of R/M HNSCC patients who have failed on first-line platinum-based therapy, confirm the clinical efficacy of afatinib observed in the Phase II proof-of-concept study, and establish a new standard of care for this patient population

Moving Atom-Field Interactions: Quantum Motional Decoherence and Relaxation

The reduced dynamics of an atomic qubit coupled both to its own quantized center of mass motion through the spatial mode functions of the electromagnetic field, as well as the vacuum modes, is calculated in the influence functional formalism. The formalism chosen can describe the entangled non-Markovian evolution of the system with a full account of the coherent back-action of the environment on the qubit. We find a slight increase in the decoherence due to the quantized center of mass motion and give a condition on the mass and qubit resonant frequency for which the effect is important. In optically resonant alkali-metal atom systems, we find the effect to be negligibly small. The framework presented here can nevertheless be used for general considerations of the coherent evolution of qubits in moving atoms in an electromagnetic field.Comment: 9 pages, 1 figure, minor change

Extended thromboprophylaxis with betrixaban in acutely ill medical patients

BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS: Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. RESULTS: A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). CONCLUSIONS: Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218.)

Classical Stabilization of Homogeneous Extra Dimensions

If spacetime possesses extra dimensions of size and curvature radii much larger than the Planck or string scales, the dynamics of these extra dimensions should be governed by classical general relativity. We argue that in general relativity, it is highly nontrivial to obtain solutions where the extra dimensions are static and are dynamically stable to small perturbations. We also illustrate that intuition on equilibrium and stability built up from non-gravitational physics can be highly misleading. For all static, homogeneous solutions satisfying the null energy condition, we show that the Ricci curvature of space must be nonnegative in all directions. Much of our analysis focuses on a class of spacetime models where space consists of a product of homogeneous and isotropic geometries. A dimensional reduction of these models is performed, and their stability to perturbations that preserve the spatial symmetries is analyzed. We conclude that the only physically realistic examples of classically stabilized large extra dimensions are those in which the extra-dimensional manifold is positively curved.Comment: 25 pages; minor changes, improved reference